Compare Ecolab Inc. (ECL) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Tango Therapeutics Inc. — how do they compare? Ecolab Inc. trades at $288.87 (market cap $80.08B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Ecolab Inc. is far larger — about 21.4× Tango Therapeutics Inc.'s market cap, and Ecolab Inc. pays a 1.02% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 91 Days and Tango Therapeutics Inc. for 0 Days on average.
| ECL | TNGX | |
|---|---|---|
Market Cap | $80.08B | $3.75B |
Volume | 1,150,296 | 9,619,106 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $32.90 |
52-Week Low | $245.73 | $7.50 |
Typical Hold Time | 91 Days | 0 Days |
Enterprise Value | $88.86B | $2.77B |
Dividend Yield | 1.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $287.79, up 1.23% today, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals, including a 12.57% net income margin and 21.85% ROE, with revenue growth from $16.08B in 2025 to a projected $16.8B in 2026. Recent news highlights its dividend consistency and High-Tech segment growth, while institutional buying and insider purchases reflect confidence.
Outlook is positive with a consensus price target of $326.38, implying 13% upside, driven by earnings beats and digital expansion. Risks include elevated P/E of 38.34 and rising debt from the CoolIT acquisition. The stock remains a buy for growth-oriented investors, balancing steady cash flows with execution risks in a competitive market.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
